4.2 Meeting Abstract

Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data

Journal

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 23, Issue -, Pages S336-S337

Publisher

CIG MEDIA GROUP, LP

Keywords

CML; chronic myeloid leukemia; mutation; protein kinase inhibitor; antineoplastic; ponatinib

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available